A supratherapeutic dose of the janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants

Journal of Clinical Pharmacology

Volumn 51, Issue 9, 2011, Pages 1256-1263

  Krishnaswami, Sriram ^a   Kudlacz, Elizabeth ^a   Wang, Rong ^a   Chan, Gary ^a  

^a PFIZER INC   (United States)

Author keywords

CP 690,550; Janus kinase; phase 1; QTc interval; tasocitinib

Indexed keywords

CYTOCHROME P450 2C19; MOXIFLOXACIN; PLACEBO; TASOCITINIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PHARMACOKINETICS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; JANUS KINASE 3; LONG QT SYNDROME; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SYSTOLE; YOUNG ADULT;

EID: 80051774422     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010379809     Document Type: Article

References (17)

1. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signalling. Immunol Rev. 2009 ; 228: 273-287
2. Karaman MW, Herrgard S, Treiber DK, et al. A qualitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 ; 26: 127-132
3. Boy M, Wang C, Wilkinson B, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009 ; 129: 2299-2302
4. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008 ; 84: 475-480
5. Modi NB, Nath R, Staehr P, Gupta SK, Aquilina JW, Rivas D. Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. J Clin Pharmacol. 2009 ; 49: 634-642
6. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006 ; 46: 498-507
7. Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004 ; 44: 464-473 (Pubitemid 38509714)
8. Serra DB, Affrime MB, Bedigian MP, et al. QT and ATc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M2 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005 ; 45: 1038-1047 (Pubitemid 41192363)
9. Extraminana F, Maison-Blanche P, Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther. 2005 ; 77: 247-258 (Pubitemid 40470381)
10. Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007 ; 81: 377-385 (Pubitemid 46364489)
11. Bloomfield DM, Krishna R, Hreniuk D, et al. Thorough QT study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol. 2009 ; 49: 937-946
12. Sechaud R, Dumotrier T, Balez S. Deferasirox does not include QT/WTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther. 2009 ; 47: 321-327
13. Damle B, Fosser C, Ito K, et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol. 2009 ; 49: 291-300
14. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007 ; 49: 146-153 (Pubitemid 46579948)
15. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008 ; 48: 726-733 (Pubitemid 351713160)
16. Dowty M, Ghosh S, Warner J, et al. Preclinical to clinical PK/PD translation of the JAK inhibitor CP-690,550 in rodent models of rheumatoid arthritis. Paper presented at the ACR Annual Scientific Meeting ; Philadelphia, PA ;..
17. Fosser C, Duczynski G, Agin M, Wicker P, Darpo B. Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies. Clin Pharmacol Ther. 2009 ; 86: 503-506